FINWIRES · TerminalLIVE
FINWIRES

Achieve Life Sciences' Cytisinicline to Unlock $760 Million Market Opportunity in Smoking Cessation, Morgan Stanley Says

By

Achieve Life Sciences' (ACHV) Cytisinicline treatment for smoking cessation in adults will unlock about a $760 million market opportunity for the company, Morgan Stanley said in a Thursday note.

The company plans to resubmit the new drug application for Cytisinicline in Q4, with potential approval from the US Food and Drug Administration in H1 2027, the brokerage noted.

Achieve Life Sciences has developed an improved formulation and simpler treatment schedule for the drug, with its phase 3 study demonstrating "significantly greater" smoking abstinence rates compared with placebo, Morgan Stanley said

The company is also evaluating Cytisinicline in e-cigarette cessation, potentially unlocking an additional $330 million market opportunity, the investment firm added.

Morgan Stanley initiated coverage on Achieve Life Sciences with an overweight rating and a $13 price target.

Price: $7.08, Change: $+0.39, Percent Change: +5.81%

Related Articles

Wire

GBM Resources Confirms Continuation of Prospective Gold Host at Queensland Project; Shares Down 5%

GBM Resources (ASX:GBM) confirmed the continuation of the prospective Milled Matrix Breccia host horizon at least 700 meters south of the 309 mineral resource at the Stella prospect, expanding the exploration footprint at the Twin Hills project in Queensland, according to a Thursday filing with the Australian bourse.The company intersected gold mineralization during step-out drilling, with assays returning 8 meters at 1.31 grams per tonne grade of gold from 126 meters, the filing said.Further assays are expected to be released in the next two weeks, per the filing.Shares fell 5% in midday trade Thursday.

ASX:GBM
Wire

Pan American Silver Q2 Adjusted Earnings, Revenue Rise; Shares Drop After Hours

Pan American Silver (PAAS) reported Q2 adjusted earnings late Wednesday of $0.73 per basic share, up from $0.43 a year earlier.Analysts polled by FactSet expected $0.88.Revenue for the quarter ended June 30 rose to $1.12 billion from $812 million a year earlier.Three analysts expected $1.15 billion.The company raised its quarterly dividend to $0.184 a share from $0.18, payable around Sept. 4 to stockholders of record Aug. 24.Pan American Silver shares fell 5.1% in after-hours trading.

$PAAS
Wire

Stantec Q2 Adjusted Earnings, Revenue Rise

Stantec (STN) reported Q2 adjusted earnings late Wednesday of 1.61 Canadian dollars ($1.15) per diluted share, up from CA$1.36 a year earlier.Analysts surveyed by FactSet expected CA$1.58.Net revenue in the three months ended June 30 rose to CA$1.78 billion from CA$1.6 billion a year earlier.Analysts projected CA$1.79 billion.Stantec shares rose 1.3% in after-hours trading.

$STN